FY2020 Earnings Forecast for TherapeuticsMD Inc Issued By Jefferies Financial Group (TXMD)

TherapeuticsMD Inc (NASDAQ:TXMD) – Analysts at Jefferies Financial Group reduced their FY2020 earnings per share estimates for TherapeuticsMD in a report released on Tuesday, August 14th. Jefferies Financial Group analyst M. Andrews now expects that the company will post earnings per share of $0.14 for the year, down from their previous estimate of $0.19. Jefferies Financial Group also issued estimates for TherapeuticsMD’s FY2021 earnings at $0.83 EPS and FY2022 earnings at $1.39 EPS.

TherapeuticsMD (NASDAQ:TXMD) last announced its quarterly earnings data on Monday, July 30th. The company reported ($0.15) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.03). The firm had revenue of $3.80 million during the quarter, compared to analyst estimates of $4.23 million. TherapeuticsMD had a negative net margin of 582.86% and a negative return on equity of 80.75%. The firm’s revenue for the quarter was down 11.6% on a year-over-year basis. During the same period in the prior year, the company posted ($0.10) earnings per share.



Other research analysts have also issued reports about the company. Cantor Fitzgerald increased their price objective on TherapeuticsMD from $26.00 to $27.00 and gave the company an “overweight” rating in a report on Tuesday. Oppenheimer set a $10.00 price objective on TherapeuticsMD and gave the company a “buy” rating in a report on Thursday, May 3rd. ValuEngine lowered TherapeuticsMD from a “buy” rating to a “hold” rating in a report on Saturday, July 28th. BidaskClub raised TherapeuticsMD from a “sell” rating to a “hold” rating in a report on Friday, June 8th. Finally, Zacks Investment Research raised TherapeuticsMD from a “sell” rating to a “hold” rating in a report on Wednesday, May 9th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and eight have issued a buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $14.75.

Shares of TXMD stock traded down $0.17 during mid-day trading on Wednesday, reaching $5.32. The stock had a trading volume of 20,267 shares, compared to its average volume of 2,527,139. The company has a debt-to-equity ratio of 0.94, a quick ratio of 7.79 and a current ratio of 7.88. The firm has a market capitalization of $1.21 billion, a PE ratio of -14.70 and a beta of 1.53. TherapeuticsMD has a 1-year low of $4.34 and a 1-year high of $7.66.

Several institutional investors and hedge funds have recently modified their holdings of the company. Cetera Advisors LLC boosted its stake in shares of TherapeuticsMD by 18.1% in the first quarter. Cetera Advisors LLC now owns 57,450 shares of the company’s stock worth $281,000 after buying an additional 8,800 shares during the last quarter. ING Groep NV boosted its stake in shares of TherapeuticsMD by 3.4% in the first quarter. ING Groep NV now owns 278,138 shares of the company’s stock worth $1,355,000 after buying an additional 9,176 shares during the last quarter. Swiss National Bank boosted its stake in shares of TherapeuticsMD by 4.0% in the first quarter. Swiss National Bank now owns 301,400 shares of the company’s stock worth $1,468,000 after buying an additional 11,600 shares during the last quarter. Iridian Asset Management LLC CT boosted its stake in shares of TherapeuticsMD by 20.3% in the second quarter. Iridian Asset Management LLC CT now owns 68,841 shares of the company’s stock worth $430,000 after buying an additional 11,629 shares during the last quarter. Finally, OppenheimerFunds Inc. boosted its stake in shares of TherapeuticsMD by 0.7% in the first quarter. OppenheimerFunds Inc. now owns 1,646,316 shares of the company’s stock worth $8,017,000 after buying an additional 12,236 shares during the last quarter. Hedge funds and other institutional investors own 72.13% of the company’s stock.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc operates as a women's health care product company. Its pipeline of hormone therapy drug candidates include TX-001HR, a combination of estradiol and progesterone drug candidate under clinical trials for the treatment of moderate to severe vasomotor symptoms due to menopause; TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil; and TX-004HR, an applicator-free vaginal estradiol softgel drug candidate for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy in post-menopausal women with vaginal linings that do not receive enough estrogen.

Featured Article: Using the New Google Finance Tool

Earnings History and Estimates for TherapeuticsMD (NASDAQ:TXMD)

Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply